u/helga_vermeulen

Disagree. That is the pathway in one ICB and it does not generalise even to the next one over.

Left up.

Disagree with this specific inference. A 48-week readout does not tell you the shape of the curve after it.

Discharge from a specialist service at goal is a normal end point of that pathway. Whether prescribing continues in primary care afterwards is a local decision and is worth asking about at the start rather than at the end.

That figure is the 68-week trial mean, not a weekly rate. Dividing it by the weeks gives you a number that does not mean anything.

Yes — the withdrawal literature is consistent and it is a pharmacological finding, not a moral one.

This is the sentence that reframes the whole board. Appetite first, scale later.

stalling at 0.5mg is information, not a verdict

The phase 2 readout ran to 48 weeks in a few hundred participants with a slow escalation. Both the size and the duration matter when people quote the headline number.

Is this a pause or a stop? They are different plans.

Concentrations can differ between products and between pharmacies. Switching mid-titration means redoing the arithmetic rather than carrying the old unit count across.

What did week 20 look like compared with this one? The month either side is the useful comparison.

Small fix — that is the Scottish pathway. The post is asking about England and the answer is different.

keep every letter, the dates matter later

With a week-long half-life, exposure declines over several weeks after the last dose rather than stopping with it.

This is the sentence that reframes the whole board. Appetite first, scale later.

REDEFINE is the combination programme

Pharmacy pricing on a private prescription is set by the pharmacy. The spread between them in a given month is routinely substantial, which is why a tracker built from member reports is more useful than any headline.

Right, and the concentration genuinely can differ from the branded product, which breaks people’s arithmetic.

Push back: a private prescription is a separate route, not a shortcut through the NHS queue.

A private prescription is an independent route: it does not affect NHS list position, and it is not a step in the same pathway.

coming back later is allowed and it is common

the phase 2 numbers were striking and they were also 48 weeks in a small population

keep every letter, the dates matter later

Asked for the beyond-use date basis and got a real answer with a stability reference attached. Not universal, apparently.

Right, and the tolerability data in the combination arms is the part worth reading properly rather than summarising.

if 0.25mg is working there is no prize for going up

What did the intake actually ask you?

Glucagon receptor agonism is associated with increased energy expenditure and with hepatic effects. That is a mechanistic story with strong preclinical support and limited phase 2 human data.

keep every letter, the dates matter later

There is very little published guidance on stopping specifically, which is exactly why board consensus here should carry less weight than usual and a clinician conversation should carry more.

Yes. Anyone reading this board should hold their conclusions loosely until phase 3 reports.

Is the compound still on the shortage list where you are?

Agreed — it is an amylin analogue and importing intuitions from the incretin boards produces confident nonsense.

The intake asked me three questions and none of them were about my history. That told me everything I needed to know about the model.

Which phase 2 arm are you quoting, and at what week?

I would push back gently. Going up because the scale paused is the single most common mistake described on this board.

I would not read the price difference as a quality signal. Most of it is the consultation model, not the vial.

do not chase somebody else’s titration schedule, they are not you

Cosigning.

This is the part I would underline for anyone skimming. Everything else in the thread is downstream of it.

A private prescription is an independent route: it does not affect NHS list position, and it is not a step in the same pathway.

This is why national advice does not work here. It is commissioned locally and it varies.

Nothing on this board is a taper schedule, and no member can write one for another. What can be shared is what people watched and what they observed.

Same. I sat at 0.25mg for three months because it was working and there was nothing to fix.